These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 30407259)

  • 21. From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting.
    Mumolo MG; Bertani L; Ceccarelli L; Laino G; Di Fluri G; Albano E; Tapete G; Costa F
    World J Gastroenterol; 2018 Sep; 24(33):3681-3694. PubMed ID: 30197475
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of fecal calprotectin and lactoferrin in patients with IBD. Review.
    Stragier E; Van Assche G
    Acta Gastroenterol Belg; 2013 Sep; 76(3):322-8. PubMed ID: 24261027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Faecal lactoferrin--a novel test to differentiate between the irritable and inflamed bowel?
    Sidhu R; Wilson P; Wright A; Yau CW; D'Cruz FA; Foye L; Morley S; Lobo AJ; McAlindon ME; Sanders DS
    Aliment Pharmacol Ther; 2010 Jun; 31(12):1365-70. PubMed ID: 20331581
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation.
    Chung-Faye G; Hayee B; Maestranzi S; Donaldson N; Forgacs I; Sherwood R
    Inflamm Bowel Dis; 2007 Nov; 13(11):1374-8. PubMed ID: 17577247
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fecal lactoferrin as a noninvasive biomarker in inflammatory bowel diseases.
    Langhorst J; Boone J
    Drugs Today (Barc); 2012 Feb; 48(2):149-61. PubMed ID: 22384454
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Calprotectin or Lactoferrin: Do They Help.
    Wright EK
    Dig Dis; 2016; 34(1-2):98-104. PubMed ID: 26982329
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Automated Fecal Biomarker Profiling - a Convenient Procedure to Support Diagnosis for Patients with Inflammatory Bowel Diseases.
    Kraemer A; Bulgakova T; Schukina O; Kharitidis A; Kharitonov A; Korostovtseva E; Hammar F; Bang H; Lapin S
    Clin Lab; 2020 Jul; 66(7):. PubMed ID: 32658433
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The prevalence of irritable bowel syndrome-type symptoms in inflammatory bowel disease patients in remission.
    Hoekman DR; Zeevenhooven J; D'Haens GR; Benninga MA
    Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1086-1090. PubMed ID: 28639969
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ACG Clinical Guideline: Management of Irritable Bowel Syndrome.
    Lacy BE; Pimentel M; Brenner DM; Chey WD; Keefer LA; Long MD; Moshiree B
    Am J Gastroenterol; 2021 Jan; 116(1):17-44. PubMed ID: 33315591
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome.
    Sydora MJ; Sydora BC; Fedorak RN
    J Crohns Colitis; 2012 Mar; 6(2):207-14. PubMed ID: 22325175
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
    D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
    Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic value of calprotectin in irritable bowel syndrome and in inflammatory bowel disease.
    Grad C; David L; Portincasa P; Dumitraşcu DL
    Rom J Intern Med; 2012; 50(1):3-6. PubMed ID: 22788087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Utility of Fecal Markers to Diagnose and Monitor Inflammatory Bowel Diseases.
    Sorrentino D; Franck C
    Am J Gastroenterol; 2015 Dec; 110(12):1732-3. PubMed ID: 26673502
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical value of fecal calprotectin.
    Ricciuto A; Griffiths AM
    Crit Rev Clin Lab Sci; 2019 Aug; 56(5):307-320. PubMed ID: 31088326
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FECAL CALPROTECTIN: levels for the ethiological diagnosis in Brazilian patients with gastrointestinal symptoms.
    Kotze LM; Nisihara RM; Marion SB; Cavassani MF; Kotze PG
    Arq Gastroenterol; 2015; 52(1):50-4. PubMed ID: 26017083
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical outcomes at 12 months and risk of inflammatory bowel disease in patients with an intermediate raised fecal calprotectin: a 'real-world' view.
    McFarlane M; Chambers S; Malik A; Lee B; Sung E; Nwokolo C; Waugh N; Arasaradnam R
    BMJ Open; 2016 Jun; 6(6):e011041. PubMed ID: 27266773
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease.
    Konikoff MR; Denson LA
    Inflamm Bowel Dis; 2006 Jun; 12(6):524-34. PubMed ID: 16775498
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Volatile organic compounds as potential biomarkers of irritable bowel syndrome: A systematic review.
    Zhang VR; Ramachandran GK; Loo EXL; Soh AYS; Yong WP; Siah KTH
    Neurogastroenterol Motil; 2023 Jul; 35(7):e14536. PubMed ID: 36780514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical utility of the assessment of fecal calprotectin in Leśniowski-Crohn's disease.
    Eder P; Stawczyk-Eder K; Krela-Kaźmierczak I; Linke K
    Pol Arch Med Wewn; 2008 Nov; 118(11):622-6. PubMed ID: 19140565
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FOCUS: Future of fecal calprotectin utility study in inflammatory bowel disease.
    Rosenfeld G; Greenup AJ; Round A; Takach O; Halparin L; Saadeddin A; Ho JK; Lee T; Enns R; Bressler B
    World J Gastroenterol; 2016 Sep; 22(36):8211-8. PubMed ID: 27688663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.